BR112021018211A2 - Revestimento reversível de nanopartículas de quitosana-ácido nucléico e métodos de seu uso - Google Patents

Revestimento reversível de nanopartículas de quitosana-ácido nucléico e métodos de seu uso

Info

Publication number
BR112021018211A2
BR112021018211A2 BR112021018211A BR112021018211A BR112021018211A2 BR 112021018211 A2 BR112021018211 A2 BR 112021018211A2 BR 112021018211 A BR112021018211 A BR 112021018211A BR 112021018211 A BR112021018211 A BR 112021018211A BR 112021018211 A2 BR112021018211 A2 BR 112021018211A2
Authority
BR
Brazil
Prior art keywords
chitosan
nucleic acid
methods
reversible
nanoparticle coating
Prior art date
Application number
BR112021018211A
Other languages
English (en)
Inventor
Anthony Cheung
Carlos Fleet
Daniel Veilleux
Chin Mun Tam Natalie
Lian Ma Pei
Krishnan Gopalakrishna Panicker Rajesh
Original Assignee
Engene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engene Inc filed Critical Engene Inc
Publication of BR112021018211A2 publication Critical patent/BR112021018211A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Manufacturing & Machinery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

revestimento reversível de nanopartículas de quitosana-ácido nucléico e métodos de seu uso. composições poliplex de quitosana-ácido nucleico contendo um revestimento de polímero ligado reversivelmente compreendendo copolímeros em bloco lineares com uma região de âncora polianiônica e pelo menos uma região de cauda de polietileno glicol são descritas neste documento. em alguns casos, as composições exibem estabilidade e/ou difusão na mucosa melhoradas em comparação com partículas não revestidas. em alguns casos, o revestimento de polímero ligado reversivelmente não interfere, nem intensifica, transfecção de células ou tecidos alvo em comparação com partículas não revestidas.
BR112021018211A 2019-03-14 2020-03-13 Revestimento reversível de nanopartículas de quitosana-ácido nucléico e métodos de seu uso BR112021018211A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962818425P 2019-03-14 2019-03-14
US201962923403P 2019-10-18 2019-10-18
US201962924131P 2019-10-21 2019-10-21
PCT/IB2020/000175 WO2020183238A1 (en) 2019-03-14 2020-03-13 Reversible coating of chitosan-nucleic acid nanoparticles and methods of their use

Publications (1)

Publication Number Publication Date
BR112021018211A2 true BR112021018211A2 (pt) 2021-11-23

Family

ID=72426073

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112021018211A BR112021018211A2 (pt) 2019-03-14 2020-03-13 Revestimento reversível de nanopartículas de quitosana-ácido nucléico e métodos de seu uso
BR112021018186A BR112021018186A2 (pt) 2019-03-14 2020-03-13 Expressão localizada à base de poliplex de quitosana de il-12 sozinho ou em combinação com indutores ifn tipo-i para tratamento de cânceres de mucosa

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112021018186A BR112021018186A2 (pt) 2019-03-14 2020-03-13 Expressão localizada à base de poliplex de quitosana de il-12 sozinho ou em combinação com indutores ifn tipo-i para tratamento de cânceres de mucosa

Country Status (12)

Country Link
US (2) US20220370637A1 (pt)
EP (2) EP3937981A4 (pt)
JP (2) JP2022524859A (pt)
KR (2) KR20210151822A (pt)
CN (2) CN113874049A (pt)
AU (2) AU2020234067A1 (pt)
BR (2) BR112021018211A2 (pt)
CA (2) CA3133175A1 (pt)
IL (2) IL286320A (pt)
MX (2) MX2021010993A (pt)
SG (2) SG11202110007VA (pt)
WO (2) WO2020183239A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024507363A (ja) * 2021-02-18 2024-02-19 エンジーン，インコーポレイティド 転移性がん治療のための併用遺伝子治療
NL2031209B1 (en) * 2022-03-09 2023-09-18 20Med Therapeutics B V Polymer-coated nanoparticles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595303B1 (en) * 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
US8461316B1 (en) * 2005-01-04 2013-06-11 Gp Medical, Inc. Nanoparticles for delivery of bioactive agents
US9144546B2 (en) * 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
PT2828332T (pt) * 2012-03-21 2017-08-10 Engene Inc Nanopartículas de quitosano duplamente derivado e métodos para produzir e utilizar as mesmas para transferência de gene in vivo
PT3049473T (pt) * 2013-09-25 2021-12-21 Engene Inc Nanopartículas de quitosana duplamente derivada e métodos de produção e utilização das mesmas para transferência de genes in vivo
BR112016011930A2 (pt) * 2013-12-23 2017-09-26 Alk Abello As combinações de peptídeos e seus usos em tratamento de alergia de ácaro de poeira
US20180028458A1 (en) * 2015-02-09 2018-02-01 Polyvalor, Société En Commandite (S.E.C.) Coated chitosan-based polyplex for delivery of nucleic acids
CA3013467A1 (en) * 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
SI3458083T1 (sl) * 2016-05-18 2023-03-31 Modernatx, Inc. Polinukleotidi, ki kodirajo interlevkin-12 (IL12) in njihova uporaba
KR101870025B1 (ko) * 2016-06-27 2018-06-21 영남대학교 산학협력단 알부민 접합체의 층상 자가조립체 및 이를 이용한 약제학적 조성물
KR102627347B1 (ko) * 2017-01-27 2024-01-22 더 메서디스트 하스피틀 면역 요법을 위한 코어/쉘 구조 플랫폼
US10736957B2 (en) * 2017-12-19 2020-08-11 President And Fellows Of Harvard College Enhanced immunogenicity of mRNA with co-encoded adjuvant sequences
EP3796891A4 (en) * 2018-04-11 2022-04-20 Precision Molecular Inc. THERAPEUTIC CONSTRUCTIONS FOR THE TREATMENT OF CANCER
US20210154328A1 (en) * 2018-04-11 2021-05-27 Cancer Targeting System, Inc. Therapeutic constructs for treating cancer
EP3897700A4 (en) * 2018-12-17 2023-05-10 Immune Design Corp. PATHOGEN-ASSOCIATED MOLECULAR SAMPLE AND RNA-IMMUNOGENIC COMPOSITIONS AND METHODS OF USE OF THE COMPOSITIONS TO TREAT CANCER
CN110011092B (zh) * 2019-03-22 2021-08-20 富士康(昆山)电脑接插件有限公司 电连接器

Also Published As

Publication number Publication date
EP3937982A1 (en) 2022-01-19
IL286320A (en) 2021-10-31
EP3937982A4 (en) 2024-02-21
JP2022524859A (ja) 2022-05-10
SG11202110008TA (en) 2021-10-28
KR20210151822A (ko) 2021-12-14
IL286319A (en) 2021-10-31
BR112021018186A2 (pt) 2021-11-30
EP3937981A1 (en) 2022-01-19
SG11202110007VA (en) 2021-10-28
KR20210152480A (ko) 2021-12-15
CA3133175A1 (en) 2020-09-17
EP3937981A4 (en) 2023-03-15
CN114173769A (zh) 2022-03-11
JP2022525866A (ja) 2022-05-20
WO2020183239A1 (en) 2020-09-17
CN113874049A (zh) 2021-12-31
US20220370637A1 (en) 2022-11-24
WO2020183238A1 (en) 2020-09-17
US20220395584A1 (en) 2022-12-15
AU2020235503A1 (en) 2021-10-07
MX2021010995A (es) 2021-12-10
CA3133177A1 (en) 2020-09-17
MX2021010993A (es) 2021-12-10
AU2020234067A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
BR112021018211A2 (pt) Revestimento reversível de nanopartículas de quitosana-ácido nucléico e métodos de seu uso
WO2017143042A3 (en) Compositions for enhancing targeted gene editing and methods of use thereof
Xu et al. Nanocomposite hydrogels with high strength cross-linked by titania
BRPI0703508A (pt) copolìmero em emulsão aquosa, anfifìlico, e, método para produzir copolìmero em emulsão, anfifìlico
BRPI0716156A8 (pt) Composição compreendendo nanopartículas tipo núcleo-casca, método para a preparação da referida composição e revestimento
WO2020102503A3 (en) Fusosome compositions for t cell delivery
BR0303452A (pt) Composição polimérica, partìcula compósita, composição aquosa, e, partìcula polimérica de estágios múltiplos
NZ708247A (en) Hyaluronic acid based formulations
BRPI0511593A (pt) formulações estáveis durante a transição do veìculo hidrofóbico para o meio hidrofìlico
Liu et al. Construction of antibody-like nanoparticles for selective protein sequestration in living cells
ATE422880T1 (de) Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen
WO2007142797A3 (en) Medical electrode containing a hydrophilic polymer
WO2008063418A3 (en) Modified two-component gelation systems, methods of use and methods manufacture
WO2009026543A3 (en) Cationic alpha-amino acid-containing biodegradable polymer gene transfer compositions
US10414877B2 (en) Hydrogel-formable composition and high strength hydrogel formed from the same
ES2572277T3 (es) Composiciones fijadoras para el cabello
WO2021134023A3 (en) Compositions and methods for nucleic acid delivery
MX2023002107A (es) Composiciones y metodos para la generacion in vivo de celulas que expresan car.
WO2019210326A3 (en) Cationic polymer and use for biomolecule delivery
CN103409479B (zh) 增强皮肤自然补水能力、活化细胞能量的高聚合物及制备方法
BR112012017159A2 (pt) solução aquosa de polímeros ramificados combinados com fluido metacrílico, com um teor de sólidos maior do que 60%, método de fabricação e uso como um agente plastificante.
Liu et al. A targeted nanoplatform co-delivery of pooled siRNA and doxorubicin for reversing of multidrug resistance in breast cancer
WO2014105966A3 (en) Ddr2 mutations as targetable features of melanoma or basal cell carcinoma
MX2021009826A (es) Recubrimiento polimerico biocompatible que contiene agentes terapeuticos.
WO2020256287A3 (ko) 베타-사이클로덱스트린을 통한 호스트-게스트 상호작용에 의해 온도감응성 폴리포스파젠에 결합된 생리활성 물질을 포함하는 하이드로젤 포접 복합체 및 이의 용도